TARO PHARMACEUTICAL INDUSTRIES overview

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2023. Quarter ended June 30, 2023 Highlights ─ compared to June 30, 2022 Net sales increased $2.2 million, or 1.4%, to $158.9 million. Gross profit of $64.1 million (40.3% of net sales) compared to $81.6 million (52.1% of net sales). Research and development (R&D) expenses of $16.1 million increased $4.6 million. Selling, marketing,...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2023, after the close of market on Wednesday, July 26, 2023. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2023, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com . Hard copies of the report may be ordered free of charge by sending requests to: Taro Pharmaceuticals U.S.A., Inc. 3 Skyline Drive Hawthorne, NY 10532 Attn.: William J. Coote or via email to...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2023. Quarter ended March 31, 2023* Highlights ─ compared to March 31, 2022 Net sales of $146.6 million increased $3.3 million, or 2.3%. Gross profit of $75.7 million (51.6% of net sales) compared to $77.3 million (54.0% of net sales). Research and development (R&D) expenses of $16.3 million increased $1.4 million. Selling,...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2022. Quarter ended December 31, 2022* Highlights ─ compared to December 31, 2021 Net sales of $139.2 million was line with the prior year quarter. We continue to experience price pressures particularly in the U.S. generic business. Gross profit of $64.0 million (46.0% of net sales) compared to $76.0 million (54.7% of...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after the close of market on Tuesday, January 24, 2023. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2022. Quarter ended September 30, 2022* Highlights ─ compared to September 30, 2021 Net sales of $130.5 million decreased, principally due to the continued price decline particularly in the U.S. generic business, as well as a one-time gross-to-net (“GTN”) adjustment. Gross profit of $47.0 million (36.0% of net...